A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

January 10, 2025

Study Completion Date

January 10, 2025

Conditions
Huntington's Disease
Interventions
DRUG

SAGE-718

Oral softgel lipid capsules

Trial Locations (18)

14221

Sage Investigational Site, Williamsville

19107

Sage Investigational Site, Philadelphia

20007

Sage Investigational Site, Washington D.C.

23298

Sage Investigational Site, Richmond

29425

Sage Investigational Site, Charleston

33431

Sage Investigational Site, Boca Raton

33612

Sage Investigational Site, Tampa

38157

Sage Investigational Site, Memphis

43614

Sage Investigational Site, Toledo

45219

Sage Investigational Site, Cincinnati

52242

Sage Investigational Site, Iowa City

60611

Sage Investigational Site, Chicago

80113

Sage Investigational Site, Englewood

90095

Sage Investigational Site, Los Angeles

90720

Sage Investigational Site, Los Alamitos

92037

Sage Investigational Site, La Jolla

99202

Sage Investigational Site, Spokane

M2K 1E1

Sage Investigational Site, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sage Therapeutics

INDUSTRY